Takeda Pharmaceutical Company Limited Q1 FY2026 earnings call

• Strategic Roadmap & Overall Performance

  • Takeda delivered a solid Q1 FY26 start, with performance aligned with expectations and on track to meet full-year guidance, progressing steadily along the 2-Horizon strategic roadmap: Horizon One focuses on operational transformation, portfolio resilience, and launch preparation for new drugs, while Horizon Two will bring accelerated long-term growth.
  • Core financial performance was in line: slight 0.5% core revenue decline at CER was expected, as growth from in-line and new brands offset anticipated mature portfolio headwinds.
  • The enterprise transformation program is on track, with implementation of the new international business unit largely completed, bringing leadership closer to patients and improving speed, simplicity, and efficiency. Transformation savings are funding pipeline advancement and new product launch preparations.

• Pipeline & Launch Milestones

  • oveporexton (brand name ORZEYFUL) for narcolepsy type 1 (NT1) received its first approval in China, with U.S. and Japanese approvals expected in Q2 FY26, and launches in both markets planned for H2 2026. New Phase III data presented at SLEEP 2026 confirmed efficacy across all endpoints, including normalization of REM sleep latency and improvements in daily function, cognition, and patient quality of life. Pre-launch preparations are complete, with MSLs engaged for over a year, payer and KOL outreach done, and specialty pharmacy and patient support programs established.
  • rusfertide, a first-in-class hepcidin mimetic for polycythemia vera (PV), has U.S. FDA priority review with an August PDUFA date and a planned H2 2026 U.S. launch. Takeda now holds exclusive global commercialization rights after Protagonist opted out of co-commercialization. The drug delivers durable hematocrit control and reduces phlebotomy reliance, with pre-launch education and commercial preparations complete leveraging Takeda's existing hematology infrastructure.
  • zasocitinib, a best-in-class once-daily oral TYK2 inhibitor for psoriasis, demonstrated statistical superiority over deucravacitinib in a head-to-head Phase III trial, with over 35% of patients achieving complete skin clearance (PASI 100) at week 16. It is on track for a U.S. launch in H1 2027, with Phase II data for Crohn's disease and ulcerative colitis expected by the end of FY26, and additional trials ongoing across multiple immune-mediated diseases.
  • Other key pipeline progress: Initiated a Phase III trial of elritercept for first-line anemia-associated myelodysplastic syndrome (MDS), presented promising 2-year overall survival data for TAK-928 (PD-1/IL-2 bispecific) in IO-resistant non-small cell lung cancer (NSCLC) at ASCO, with a pivotal Phase III planned for later this fiscal year; arcotatug tavatecan (TAK-921) has strong Phase III data from Innovent in third-line gastric cancer, with a Japanese filing planned for FY27.

• Operational Highlights

  • Announced a landmark collaboration with the Indonesian government to build local plasma operations, starting with new donation centers and assessing future manufacturing feasibility, to support growth of Takeda's plasma-derived therapies (PDT) business and strengthen the global sustainable plasma ecosystem.

Total Q1 FY26 revenue was 1.22 trillion yen, up 10.2% on an actual FX basis and down 0.5% at constant exchange rates (CER). Core operating profit was 358.9 billion yen, up 11.5% actual FX and down 0.5% CER. Reported operating profit was 201.4 billion yen, up 9.1% year-over-year actual FX. Core EPS was 154 yen, down 11.8% CER, and reported EPS was 72 yen.

1. Core in-line brands: Represent 58% of total revenue, grew 2.3% at CER. Largest brand ENTYVIO grew 4% CER, with 6.7% growth in Europe, 10% growth in Japan, and 36% growth in intercontinental markets driven by the subcutaneous pen formulation.
2. New launches: Represent 4% of total revenue, grew 22.6% at CER, supported by FRUZAQLA, LIVTENCITY, ADZYNMA, and QDENGA.
3. Mature/LOE portfolio: Experienced continued decline driven by generic erosion of VYVANSE in the U.S., which was largely offset by growth from other segments.

• Full year FY26 financial guidance is unchanged from the May update, and Q1 performance is fully on track to meet full year targets.
• Full year adjusted free cash flow is still projected to be between 650 billion yen and 750 billion yen.
• Full year gross margin guidance is maintained at 65%, with the small one-time divestiture milestone gain in Q1 expected to be negligible for the full year. Management will update guidance if future FX movements require adjustment.
• Takeda reaffirmed its Horizon One financial commitments: return to top-line revenue growth, protect core operating profit margins, improve return on equity to above 5%, and maintain strong adjusted free cash flow.
• A Capital Markets Day has been scheduled for December 11, 2026 in Tokyo, where management will present detailed pipeline updates and mid- to long-term financial ambitions aligned with the 2-Horizon strategic roadmap through the end of the decade.

No new material risks were disclosed in this earnings call. Management reaffirmed that existing risks, including potential differences between forward-looking statements and actual results, are outlined in Takeda's recent Form 20-F and other SEC filings. The only operational headwind already priced into guidance is continued generic erosion of the mature brand VYVANSE in the U.S.

Q: Q1 gross margin came in higher than expected, how much is attributable to the one-time divestiture milestone, and is the full year 65% gross margin guidance maintained? How will ORZEYFUL be positioned and priced globally for narcolepsy type 1?

A: The one-time divestiture milestone contributed only a small portion of Q1's gross margin improvement, and it will be almost negligible for the full year. Most Q1 gross margin expansion came from favorable FX impacts on plasma-derived therapy cost of goods. The full year 65% gross margin guidance is maintained. ORZEYFUL is a first-in-class monotherapy that addresses the underlying orexin deficiency causing NT1, and is expected to redefine standard of care. Initial patient growth will come from patients already diagnosed and on existing therapy, with long-term growth coming from improved NT1 diagnosis. Pricing will balance appropriate value recognition for this transformative therapy with broad patient access, with no details shared ahead of approval.

Q: When will TAK-360 Phase II data for narcolepsy type 2 and idiopathic hypersomnia be released, and why is TAK-360 also being studied in NT1? When will zasocitinib IBD data be released?

A: TAK-360 uses an adaptive Phase II design testing once and twice daily dosing, so there is no fixed readout date, but data is expected this calendar year, and it is still unconfirmed if it will be ready in time for the December Capital Markets Day. Takeda is fully confident ORZEYFUL is best-in-class for NT1, and is studying TAK-360 to further expand understanding of orexin agonist potential across narcolepsy subtypes and dosing regimens. Zasocitinib Phase II data for both ulcerative colitis and Crohn's disease is expected by the end of FY26, with publication and presentation details still to be confirmed.

Q: What is the outlook for ENTYVIO growth, and what is rusfertide's pricing strategy?

A: ENTYVIO remains the #1 prescribed IBD therapy globally, with Q1 growth driven by strong uptake of the subcutaneous pen formulation: 6.7% growth in Europe, 10% in Japan, and 36% in intercontinental markets. U.S. Q1 sales decline at CER is due to pricing mix and lower inventory days on hand, while underlying demand remains strong, and full year guidance for ENTYVIO is on track. Like other new products, rusfertide pricing will balance appropriate value recognition with rapid patient access, with no specific details shared ahead of approval.

Q: What is the status of mezagitamab development, and what is the timeline for ENTYVIO biosimilar entry in the U.S.?

A: Mezagitamab has two ongoing Phase III trials in ITP and IgAN, with a new Phase II program recently initiated for antibody-mediated rejection. New long-term extension data confirms durable clinical effects from short-course dosing, leading to an adjusted Phase III design that will test a single 6-month course of treatment followed by patient tracking. The current peak sales estimate of $1 billion to $3 billion is unchanged, with an update planned for the December Capital Markets Day. ENTYVIO biosimilar entry in the U.S. is still expected 3 to 5 years from now, with ongoing litigation to defend Takeda's strong IP position, and no changes to the current timeline that expects entry around 2032.